Zambon heading to US market with 500m acquisition
Zambon is set to acquire respiratory company Breath Therapeutics for up to 500m to complement its respiratory pipeline and get access to the US market.
Gut microbiome boosts muscle strength
Swedish researchers have demonstrated that the gut microbiome can significantly affect the proper development and strength of skeletal muscle.
Curetis lower respiratory tract panel ready for FDA clearance
Molecular diagnostics expert Curetis NV has filed for US FDA clearance of Unyvero LRT to speed up diagnosis of patients with lower respiratory tract (LRT) infections.
Merck and Broad Institute announce CRISPR license agreement
Merck and the Broad Institute have signed an agreement on the granting of non-exclusive intellectual property licenses to CRISPR-based genome editing.
Billions for the circular economy
Together with the EIB, five of the EUs largest national promotional banks and institutions plan to invest 10bn to accelerate the transition to a sustainable and circular economy.
Genmab launches US$502m IPO
Danish cancer antibody powerhouse Genmab plans to raise US$505m in its US IPO. The money will go towards its antibody therapeutics pipeline.
AM-Pharma raises 116m for Phase III
Dutch biopharma company AM-Pharma B.V. has secured 116m to bring its acute kidney injury treatment into Phase III.
US$5bn deal for Galapagos
Belgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is paying up to US$5bn for Galapagos pipeline and drug discovery platform.
Boehringer snaps up cancer vaccine developer
German pharma major Boehringer Ingelheim has taken over Swiss cancer immunotherapy player AMAL Therapeutics.
28.5m for microalgae expert Microphyt
French microalgae specialist Microphyt has raised 28.5m to develop its microalgae portfolio for nutrition and cosmetics.